Since ALK/MET-positive RMSs may be sensitive to ALK/MET tyrosine kinase inhibitors, the present study investigated whether crizotinib was able to abolish the oncogene-dependent signalling by affecting proliferation and survival in this subset of RMS. This evidence concerns the gene ALK and Bannayan-Riley-Ruvalcaba syndrome.